Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.SSE: 688505

Report for Q1 2026

Apr 30, 2026 · Issued by Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 30, 2026

On 6ix: 6ix.com/news/report-for-q1-2026-695

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. on 6ix

Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood ConferenceApr 29
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of FZ-P001 Sodium for Injection for Visualization of Malignant Lesions during Ovarian Cancer SurgeryApr 10
Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary ProcedureMar 31
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Announcement on Change of Sponsor Representative for Continuous SupervisionFeb 10

Later from Shanghai Fudan Zhangjiang Bio Pharmaceutical

Announcement on Resignation of Senior Management MembersMay 14
Announcement on the Resignation of Core Technical PersonnelMay 29
Announcement on Convening the 2026 Semi-annual Performance BriefingAug 8
Semi-annual Report for 2026Aug 15
Announcement on Shareholding Reduction Plan by Shareholder Holding More Than 5% of the SharesAug 26

All Shanghai Fudan Zhangjiang Bio Pharmaceutical news releases

Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical into a list and get an email when it puts out news.

Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical